TrialCancer discovery2017

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Alexander Drilon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.